3 results
Approved WMOCompleted
To estimate the bleeding risk with rivaroxaban, compared with ASA, in addition to a singleantiplatelet agent (clopidogrel or ticagrelor), in subjects with a recent ACS .
Approved WMOWill not start
Primary ObjectivesThe main purpose of this study is to compare how long subjects with oesophageal cancer live overall (called overall survival, OS) or live without disease progression (called progression free survival, PFS) after receiving BMS-…
Approved WMOPending
To prospectively investigate if a treatment strategy in which two types of cytotoxic RLT, i.e., an alpha-emitter and a beta-emitter, are alternatively offered to patients with oligometastatic HSPCa, is feasible and safe